TCGX Acquisition Corp. Class A Ordinary Shares TCGX · SEC Filings

website

Blank-check company formed for the purpose of effecting a merger, acquisition, or similar business c...

Price10.05

Market Cap113.6 M

Float8.63 M

CountryUS

SectorFinancial Services

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Sep 10, 2026

News

TYPE

HEADLINE

FILED AT

8-K

TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination to Form Publicly Traded Company Focused on Migraine Treatment

Oct 19, 2026

8-K

TCGX Acquisition Corp. Announces Closing of Initial Public Offering

Aug 12, 2026

8-K

Special Purpose Acquisition Company Prices $75 Million IPO, Shares to Trade on Nasdaq Under Ticker "TCGX"

Aug 6, 2026

Prospectus

TYPE

HEADLINE

FILED AT

425

NEWForm 425 - Prospectuses and communications, business combinations

Nov 9, 2026

425

Form 425 - Prospectuses and communications, business combinations

Nov 2, 2026

425

Form 425 - Prospectuses and communications, business combinations

Oct 19, 2026

425

Form 425 - Prospectuses and communications, business combinations

Oct 19, 2026

425

Form 425 - Prospectuses and communications, business combinations

Oct 19, 2026

424B4

Form 424B4 - Prospectus [Rule 424(b)(4)]

Aug 5, 2026

Registrations

TYPE

HEADLINE

FILED AT

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Aug 4, 2026

S-1/A

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Jul 31, 2026

S-1

Form S-1 - General form for registration of securities under the Securities Act of 1933

Jul 20, 2026

DRS

Form DRS - Draft Registration Statement

Jun 23, 2026

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Aug 13, 2026

SCHEDULE 13G

BIOTECHNOLOGY VALUE FUND L P (Filed by)

Aug 12, 2026

Yu Chen-Ming (Reporting)

Aug 6, 2026

3/A

Yu Chen-Ming (Reporting)

Aug 6, 2026

Skaling Craig David (Reporting)

Aug 4, 2026

Cheng Andrew (Reporting)

Aug 4, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 5, 2026